Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach



Calcat-i-Cervera, Sandra, Rendra, Erika, Scaccia, Eleonora, Amadeo, Francesco ORCID: 0000-0002-3868-2348, Hanson, Vivien, Wilm, Bettina ORCID: 0000-0002-9245-993X, Murray, Patricia, O'Brien, Timothy, Taylor, Arthur ORCID: 0000-0003-2028-6694 and Bieback, Karen
(2023) Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach. STEM CELL RESEARCH & THERAPY, 14 (1). 120-.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Background</h4>Mesenchymal stromal cells (MSCs), commonly sourced from adipose tissue, bone marrow and umbilical cord, have been widely used in many medical conditions due to their therapeutic potential. Yet, the still limited understanding of the underlying mechanisms of action hampers clinical translation. Clinical potency can vary considerably depending on tissue source, donor attributes, but importantly, also culture conditions. Lack of standard procedures hinders inter-study comparability and delays the progression of the field. The aim of this study was A- to assess the impact on MSC characteristics when different laboratories, performed analysis on the same MSC material using harmonised culture conditions and B- to understand source-specific differences.<h4>Methods</h4>Three independent institutions performed a head-to-head comparison of human-derived adipose (A-), bone marrow (BM-), and umbilical cord (UC-) MSCs using harmonised culture conditions. In each centre, cells from one specific tissue source were isolated and later distributed across the network to assess their biological properties, including cell expansion, immune phenotype, and tri-lineage differentiation (part A). To assess tissue-specific function, angiogenic and immunomodulatory properties and the in vivo biodistribution were compared in one expert lab (part B).<h4>Results</h4>By implementing a harmonised manufacturing workflow, we obtained largely reproducible results across three independent laboratories in part A of our study. Unique growth patterns and differentiation potential were observed for each tissue source, with similar trends observed between centres. Immune phenotyping verified expression of typical MSC surface markers and absence of contaminating surface markers. Depending on the established protocols in the different laboratories, quantitative data varied slightly. Functional experiments in part B concluded that conditioned media from BM-MSCs significantly enhanced tubulogenesis and endothelial migration in vitro. In contrast, immunomodulatory studies reported superior immunosuppressive abilities for A-MSCs. Biodistribution studies in healthy mice showed lung entrapment after administration of all three types of MSCs, with a significantly faster clearance of BM-MSCs.<h4>Conclusion</h4>These results show the heterogeneous behaviour and regenerative properties of MSCs as a reflection of intrinsic tissue-origin properties while providing evidence that the use of harmonised culture procedures can reduce but do not eliminate inter-lab and operator differences.

Item Type: Article
Uncontrolled Keywords: Mesenchymal stromal cells (MSCs), Tissue source, Multicentre comparison, Manufacturing, Harmonisation, Angiogenesis, Immunomodulation, In vivo distribution
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 09 May 2023 13:40
Last Modified: 29 May 2023 18:03
DOI: 10.1186/s13287-023-03352-1
Open Access URL: https://stemcellres.biomedcentral.com/articles/10....
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3170229